165 related articles for article (PubMed ID: 18923360)
1. Focus on urinary bladder cancer markers: a review.
Ecke TH
Minerva Urol Nefrol; 2008 Dec; 60(4):237-46. PubMed ID: 18923360
[TBL] [Abstract][Full Text] [Related]
2. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer.
Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
J Urol; 1999 Dec; 162(6):1951-6. PubMed ID: 10569545
[TBL] [Abstract][Full Text] [Related]
3. [Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].
Sánchez-Carbayo M; Urrutia M; Hernández-Cerceño ML; González de Buitrago JM; Navajo JA
Med Clin (Barc); 2000 Mar; 114(10):361-6. PubMed ID: 10786344
[TBL] [Abstract][Full Text] [Related]
4. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
5. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
6. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer.
Jeong S; Park Y; Cho Y; Kim YR; Kim HS
Clin Chim Acta; 2012 Dec; 414():93-100. PubMed ID: 22944145
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis].
Sun Y; He H; Ma Q; Wang XY; Yang L; He DL
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2507-12. PubMed ID: 16321281
[TBL] [Abstract][Full Text] [Related]
9. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
[TBL] [Abstract][Full Text] [Related]
10. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma.
Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
Cancer; 2001 Dec; 92(11):2820-8. PubMed ID: 11753955
[TBL] [Abstract][Full Text] [Related]
11. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
Paoluzzi M; Cuttano MG; Mugnaini P; Salsano F; Giannotti P
Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
[TBL] [Abstract][Full Text] [Related]
12. Screening for bladder cancer using urine-based tumor markers.
Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):247-53. PubMed ID: 18923361
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin-19 fragment in the diagnosis of bladder carcinoma.
Guo XG; Long JJ
Tumour Biol; 2016 Oct; 37(10):14329-14330. PubMed ID: 27448817
[TBL] [Abstract][Full Text] [Related]
15. Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests?
Pirtskalaishvili G; Konety BR; Getzenberg RH
Postgrad Med; 1999 Nov; 106(6):85-6, 91-4. PubMed ID: 10576004
[TBL] [Abstract][Full Text] [Related]
16. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
[TBL] [Abstract][Full Text] [Related]
17. Urine based markers of urological malignancy.
Konety BR; Getzenberg RH
J Urol; 2001 Feb; 165(2):600-11. PubMed ID: 11176445
[TBL] [Abstract][Full Text] [Related]
18. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.
Kenney DM; Geschwindt RD; Kary MR; Linic JM; Sardesai NY; Li ZQ
Tumour Biol; 2007; 28(2):57-62. PubMed ID: 17259754
[TBL] [Abstract][Full Text] [Related]
19. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
